In 2014, McEnaney and colleagues reported on a synthetic antibody mimic targeting prostate cancer (SyAM-P) representing a fully synthetic small-molecule fusion of CP33 [93]. This evidence concerns the gene CYP3A4 and Familial prostate cancer.